Clinigen initiates U.S. Managed Access program for TESARO’s niraparib for patients with ovarian cancer
Idis Limited | January 17, 2017
Clinigen Group plc’s (AIM: CLIN, 'Clinigen') Idis Managed Access (MA) division has partnered with TESARO Inc. (NASDAQ: TSRO), to launch a Managed Access program (also known as an expanded access program (EAP)) for the investigational PARP 1/2 inhibitor, niraparib. Niraparib is being made available for eligible women in the U.S. with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following a complete or partial response to platinum-based chemotherapy.